137 related articles for article (PubMed ID: 17914578)
1. New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients.
Itoh Y; Komohara Y; Komatsu N; Minami T; Saito K; Noguchi M; Itoh K; Harada M
Oncol Rep; 2007 Nov; 18(5):1231-7. PubMed ID: 17914578
[TBL] [Abstract][Full Text] [Related]
2. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients.
Ogata R; Matsueda S; Yao A; Noguchi M; Itoh K; Harada M
Prostate; 2004 Sep; 60(4):273-81. PubMed ID: 15264237
[TBL] [Abstract][Full Text] [Related]
3. New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles.
Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco MA; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2015 May; 26(1):133-8. PubMed ID: 25819666
[TBL] [Abstract][Full Text] [Related]
4. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.
Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Takao Y; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
Prostate; 2005 Feb; 62(3):233-42. PubMed ID: 15389794
[TBL] [Abstract][Full Text] [Related]
5. Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
Int J Oncol; 2006 Dec; 29(6):1555-60. PubMed ID: 17088996
[TBL] [Abstract][Full Text] [Related]
6. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
Harada M; Matsueda S; Yao A; Ogata R; Noguchi M; Itoh K
Oncol Rep; 2004 Sep; 12(3):601-7. PubMed ID: 15289844
[TBL] [Abstract][Full Text] [Related]
7. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer.
Matsueda S; Kobayashi K; Nonaka Y; Noguchi M; Itoh K; Harada M
Cancer Immunol Immunother; 2004 Jun; 53(6):479-89. PubMed ID: 14634796
[TBL] [Abstract][Full Text] [Related]
8. Identification of target antigens in specific immunotherapy for renal cell carcinoma.
Komohara Y; Harada M; Arima Y; Suekane S; Noguchi M; Yamada A; Itoh K; Matsuoka K
J Urol; 2007 Mar; 177(3):1157-62. PubMed ID: 17296437
[TBL] [Abstract][Full Text] [Related]
9. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.
Guo J; Li G; Tang J; Cao XB; Zhou QY; Fan ZJ; Zhu B; Pan XH
Scand J Immunol; 2013 Sep; 78(3):248-57. PubMed ID: 23721092
[TBL] [Abstract][Full Text] [Related]
10. Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.
Matsueda S; Takedatsu H; Yao A; Tanaka M; Noguchi M; Itoh K; Harada M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6933-43. PubMed ID: 16203785
[TBL] [Abstract][Full Text] [Related]
11. Identification of cyclophilin B-derived peptides capable of inducing histocompatibility leukocyte antigen-A2-restricted and tumor-specific cytotoxic T lymphocytes.
Tamura M; Nishizaka S; Maeda Y; Ito M; Harashima N; Harada M; Shichijo S; Itoh K
Jpn J Cancer Res; 2001 Jul; 92(7):762-7. PubMed ID: 11473727
[TBL] [Abstract][Full Text] [Related]
12. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
[TBL] [Abstract][Full Text] [Related]
13. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
14. Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy.
Matsueda S; Wang M; Weng J; Li Y; Yin B; Zou J; Li Q; Zhao W; Peng W; Legras X; Loo C; Wang RF; Wang HY
PLoS One; 2012; 7(9):e45756. PubMed ID: 23029225
[TBL] [Abstract][Full Text] [Related]
15. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
16. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
17. Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer.
Hayashi S; Kumai T; Matsuda Y; Aoki N; Sato K; Kimura S; Kitada M; Tateno M; Celis E; Kobayashi H
J Transl Med; 2011 Nov; 9():191. PubMed ID: 22053850
[TBL] [Abstract][Full Text] [Related]
18. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen.
Xue BH; Zhang Y; Sosman JA; Peace DJ
Prostate; 1997 Feb; 30(2):73-8. PubMed ID: 9051144
[TBL] [Abstract][Full Text] [Related]
19. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
20. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
